8-K: STAAR Surgical Reports Disappointing Q1 2025 Results, Cites China Inventory Reduction and Withdraws Financial Outlook

STAAR Surgical's Q1 2025 results were significantly impacted by planned inventory reductions in China, leading to a substantial decrease in net sales and a withdrawal of the company's financial outlook.

Summary

• STAAR Surgical reported a 45% year-over-year decrease in net sales for Q1 2025, totaling $42.6 million, primarily due to reduced channel inventory in China.
• Excluding China, net sales increased by 9% year-over-year to $42.2 million, driven by growth in other key markets.
• Gross margin decreased to 65.8% compared to 78.9% in the prior year, attributed to lower U.S. production volumes and costs associated with expanding manufacturing in Switzerland.
• The company reported a net loss of $(54.2) million, or $(1.10) per share, compared to a net loss of $(3.3) million, or $(0.07) per share, in the prior year.
• Adjusted EBITDA loss was $(26.4) million, or $(0.53) per share, versus earnings of $5.3 million, or $0.11 per share, in the prior year.
• STAAR Surgical is implementing cost control measures and restructuring activities expected to reduce the annualized SG&A run rate to approximately $225 million as the company exits fiscal 2025.
• The company has withdrawn its previously provided financial outlook due to global economic uncertainty and evolving tariff policy.
• The company's distributors in China are expected to reduce excess inventory to contracted levels by the end of the second quarter.
• The company believes it has sufficient inventory in China to meet most of its demand through the beginning of 2026 due to consignment agreements implemented to mitigate tariffs.
• The company received EVO/EVO+ ICL approval from the Taiwan FDA during the first quarter and approval in Brazil for expanded labeling.
• The company continues to believe it will receive mid-year approval for its EVO+ (V5) lenses in China.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant decline in sales and profitability, the withdrawal of the financial outlook, and the restructuring charges. However, there are some positive aspects, such as growth outside of China and cost control measures, which prevent the sentiment from being extremely negative.

Positives

• Net sales excluding China increased by 9% year-over-year, indicating growth in other key markets.
• The company is implementing cost control measures to reduce the SG&A run rate.
• The company has sufficient inventory in China to meet most demand through early 2026 due to consignment agreements.
• The company received regulatory approvals in Taiwan and Brazil for EVO/EVO+ ICL.
• EVO ICL procedure volumes in China are improving compared to the first quarter last year.

Negatives

• Net sales decreased by 45% year-over-year due to planned inventory reduction in China.
• Gross margin decreased to 65.8% from 78.9% due to lower production volumes and increased manufacturing costs in Switzerland.
• Net loss was $(54.2) million, or $(1.10) per share, compared to a net loss of $(3.3) million, or $(0.07) per share, in the prior year.
• Adjusted EBITDA loss was $(26.4) million, or $(0.53) per share, compared to earnings of $5.3 million, or $0.11 per share, in the prior year.
• The company withdrew its financial outlook due to economic uncertainty and evolving tariff policy.

Risks

• The company's reliance on independent distributors in international markets poses a risk.
• A slowdown or disruption to the Chinese economy could negatively impact sales.
• Global economic conditions and international trade disputes (including tariffs) present challenges.
• Fluctuations in foreign currency exchange rates could affect financial results.
• The willingness of surgeons and patients to adopt new or improved products and procedures is uncertain.
• Regulatory agencies have the discretion to approve or reject existing, new, or improved products.
• The company faces competition in the market.
• The company is exposed to potential losses due to product liability claims.

Future Outlook

The company withdrew its previously provided financial outlook due to global economic uncertainty and evolving tariff policy but expects to resume growth in revenue and Adjusted EBITDA for the full second half of the year.

Management Comments

• 'STAARs first quarter sales were in line with expectations, but we can and will do better,' said STAAR Surgical CEO, Stephen C. Farrell.
• Mr. Farrell continued, 'In addition, we have made excellent progress on our cost controls and restructuring activities to better align our expenses with our sales. As a result, we are confident that we will resume growth in revenue and Adjusted EBITDA for the full second half of the year.'
• 'We are proud of the great team effort to rapidly ship additional inventory into China and proactively seek ways to navigate the evolving tariff environment to support our growth plans,' said STAAR Surgical President and Chief Operating Officer, Warren Foust.
• Mr. Foust concluded, 'We believe there is a significant opportunity for STAAR to continue to drive adoption of our EVO ICLs.'

Industry Context

The announcement highlights the challenges faced by medical device companies operating in China, including inventory management, tariff mitigation, and regulatory approvals. The company's focus on cost control and restructuring reflects a broader trend in the industry to improve profitability in the face of economic uncertainty.

Comparison to Industry Standards

• Comparing STAAR Surgical's performance to competitors like Alcon, Johnson & Johnson Vision, and Carl Zeiss Meditec, the significant decline in sales and profitability in Q1 2025 is concerning.
• While these competitors also face challenges in the global market, a 45% decrease in net sales is substantial and indicates specific issues within STAAR's China operations.
• The gross margin of 65.8% is also lower than the industry average, suggesting potential inefficiencies in manufacturing and supply chain management compared to peers.
• However, STAAR's focus on a specific niche market (phakic IOLs) and its proprietary Collamer material provide a competitive advantage that could lead to future growth if the company successfully addresses its current challenges.

Stakeholder Impact

• Shareholders will be negatively impacted by the decline in sales and profitability.
• Employees may be affected by the restructuring activities and cost control measures.
• Customers may experience temporary disruptions due to inventory management in China.
• Suppliers may be affected by changes in production volumes.
• Creditors may be concerned about the company's financial performance.

Next Steps

• The company will continue to work with its distributors in China to manage inventory levels.
• The company will continue to implement cost control measures and restructuring activities.
• The company expects to receive approval for its EVO+ (V5) lenses in China.
• The company is readying its Switzerland manufacturing facility for additional production of EVO ICLs for the China market.
• The company will monitor global economic conditions and tariff policies.

Key Dates

Keywords

STAAR Surgical, EVO ICL, Financial Results, China, Inventory, Tariffs, Myopia, Vision Correction, Regulatory Approvals, SG&A, EBITDA